Nandro 300 is an injectable anabolic preparation containing a short-acting and a long-acting nandrolone ester. The short-acting phenylpropionate ester provides a rapid increase in serum nandrolone levels followed by a long-acting enanthate ester with a duration of action of 5 to 8 days. Nandro 300 has the advantage of faster onset than the traditional nandrolone decanoate and faster clearance. Nandro 300 accelerates muscle growth, stimulates appetite, increases red blood cell production, and improves bone density.
Anabolic steroids are synthetic derivatives of testosterone. Certain clinical effects and adverse reactions demonstrate the androgenic properties of these drugs. Complete dissociation of anabolic and androgenic effects has not been achieved. The actions of anabolic steroids are thus similar to those of male sex hormones. Anabolic steroids suppress the gonadotropic functions of the pituitary and may exert a direct effect upon the testes. During exogenous administration of anabolic androgens, endogenous testosterone release is inhibited through inhibition of pituitary luteinizing hormone (LH). At large doses, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle-stimulating hormone (FSH).
Nandro 300 is a sex steroid derivative with anabolic, androgenic, and progestin based activity. Nandrolone binds to androgen receptors increasing nitrogen retention and increasing protein synthesis in muscle cells resulting in increased strength and growth of muscle tissue. Some nandrolone metabolic byproducts are suspected to act as synthetic progestins which may explain the subjective claims of joint comfort reported with nandrolone use. Nandrolone is subject to hepatic metabolism.
Osteoporosis due to androgen deficiency in hypogonadal males.
Treatment of anemia in cases of renal insufficiency where oxymetholone is contraindicated.
Restoration of muscle mass in patients with muscular atrophy after traumatic recovery.
Male: Gynecomastia, excessive frequency and duration of penile erections, oligospermia.
Skin and Appendages: Hirsutism, male pattern baldness and acne, gynecomastia.
Fluid/electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.
Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests; rarely, hepatocellular neoplasms, peliosis hepatitis, hepatic adenomas, and cholestatic hepatitis.
Hematologic: Suppression of clotting factors II, V, VII, & X; bleeding in patients on anti-coagulant therapy.
Nervous System: Increased or decreased libido, headache, anxiety, depression, and generalized paresthesia.
Other: Serum lipid changes, hypercalcaemia, hypertension, oedema, priapism, and potentiation of sleep apnea.
Not for use in women or children.
Patients with known hypersensitivity to any ingredients in this product.
Patients with known or suspected prostatic, testicular, hepatic, or mammary carcinoma.
Patients with nephrosis or the nephrotic phase of nephritis, hypercalcaemia, oedema, jaundice, or liver or kidney disease with impaired bilirubin excretion.
Products containing androgens should not be used in women as they may cause virilization and fetal harm.
Latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine or a history of these conditions, since anabolic steroids may induce salt and fluid retention.
Because androgens may alter serum cholesterol concentration, caution should be used when administering these drugs to patients with a history of myocardial infarction or coronary artery disease.
Patients on oral anticoagulant therapy require close monitoring especially when androgens are started or stopped.
Diabetics: androgens may alter the metabolism of oral hypoglycemic agents or may change insulin sensitivity in patients with diabetes mellitus which may require adjustment of dosage of insulin and other hypoglycemic drugs.
Oral hypoglycemic agents: may inhibit the metabolism of oral hypoglycemic agents which may require adjustment of dosage.
Anticoagulants: Patients on anticoagulants should be carefully monitored during anabolic steroid therapy as anabolic steroids may increase sensitivity to oral anticoagulants. Patients should be monitored regularly during anabolic steroid therapy, particularly during initiation and termination of therapy.
Serum Cholesterol, HDL, LDL, TG. Hemoglobin and Hematocrit, Hepatic function tests - AST/ALT
Prostatic specific antigen - PSA, Testosterone: total, free, and bioavailable. Dihydrotestosterone & Estradiol
Male patients over 40 should undergo a digital rectal examination and evaluate PSA prior to androgen use. Periodic evaluations of the prostate should continue while on androgen therapy, especially in patients with difficulty in urination or with changes in voiding habits.
DOSAGE AND ADMINISTRATION
Adult male: 150 - 300mg injected IM every 5 - 7 days for a duration of 8 to 12 weeks.
Nandro 300 (300mg/ml) in 10ml multiple dose vial OR 10 ampules of 1ml each.
Protect from light. Store at 15 - 25oC.
PRODUCT AUTHENTICATION :
NEWS / EVENTS
Magnum Pharmaceuticals Authentication
Try our new method to quickly authenticate your product using the 2D barcode.
Click the respective link to download the QR Reader app for your phone.
Please Note : We do not sell or ship to the USA, Europe, Australia or any other locations where prohibited. All information contained within this website or in any literature provided is not a prescription to use. Please seek the advice of a physician specializing in Andrology before use.
Not affiliated with Magnum Pharma (USA), Magnum Pharmaceuticals Inc. (USA), Magnum Chemi-Tech Ltd., or Magnum Nutraceuticals (Asia) Pte Ltd.
Distributors must submit licensing, a company profile, and our completed distributor application for approval prior to ordering.